AR106863A1 - Compuestos de bencimidazol inhibidores de pad4 - Google Patents

Compuestos de bencimidazol inhibidores de pad4

Info

Publication number
AR106863A1
AR106863A1 ARP160101486A ARP160101486A AR106863A1 AR 106863 A1 AR106863 A1 AR 106863A1 AR P160101486 A ARP160101486 A AR P160101486A AR P160101486 A ARP160101486 A AR P160101486A AR 106863 A1 AR106863 A1 AR 106863A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
heterocycle
haloalkyl
nitrogen atom
Prior art date
Application number
ARP160101486A
Other languages
English (en)
Inventor
Mathew Wilson David
Roland Wellaway Christopher
Louise Walker Ann
John Sheppard Robert
Fanny Renaux Jessica
Liddle John
Stuart Garton Neil
Douault Clement
Diallo Hawa
Campbell Matthew
David Barker Michael
John Atkinson Stephen
Amans Dominique
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR106863A1 publication Critical patent/AR106863A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Son inhibidores de PAD4 y pueden ser útiles en el tratamiento de diversos trastornos, por ejemplo, artritis reumatoide, vasculitis, lupus eritematoso sistémico, colitis ulcerosa, cáncer, fibrosis quística, asma, lupus eritematoso cutáneo y psoriasis. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), y sales de estos; en donde: X es O ó S; Y es N o CR²; R¹ es -H o -C₁₋₆ alquilo; R² es -H, -OH, -C₁₋₆ alquilo, -O-C₁₋₆ alquilo, -CN, -halo, -C(=O)NH₂, -C₁₋₆ haloalquilo, -O-C₁₋₆ alquil-O-C₁₋₆ alquilo, -O-C₁₋₆ alquil-OH, -O-C₁₋₆ alquil-C(=O)NH₂, -O-C₁₋₆ alquil-CN, -O-C₁₋₆ haloalquilo, -NH-C₁₋₆ alquilo, -N(C₁₋₆ alquilo)₂ o heteroarilo; R³ es -C₁₋₆ alquilo, -C₁₋₆ alquil-NH₂ o -C₁₋₆ alquil-O-C₁₋₆ alquilo; R⁴ es H, -C₁₋₆ alquilo, -C₁₋₆ haloalquilo, -C₁₋₆ alquil-heteroarilo (en donde el grupo heteroarilo se sustituye opcionalmente con 1, 2 ó 3 grupos C₁₋₆ alquilo), -C₁₋₆ alquil-fenilo (en donde el grupo fenilo se sustituye opcionalmente con 1, 2 ó 3 sustituyentes seleccionados de la lista que consiste en halo, C₁₋₆ alquilo y -O-C₁₋₆ alquilo), -C₁₋₆ alquil-heterociclilo, -C₁₋₆ alquil-C₃₋₆ cicloalquilo, -C₁₋₆ alquil-OH, -C₁₋₆ alquil-CN o -C₁₋₆ alquil-O-C₁₋₆ alquilo; R⁵ es -H, -C₁₋₆ alquilo, -O-C₁₋₆ alquilo, -OH, -halo o -CN; o R⁴ junto con R⁵ son -(R⁴)-CH₂CH₂O-(R⁵)-, -(R⁴)-CH₂CH₂CH₂O-(R⁵)- o -(R⁴)-CH(Me)CH₂O-(R⁵)-, en donde -(R⁴)- y -(R⁵)- indican las posiciones de unión de la cadena de alqueniloxi a los respectivos átomos del anillo; R⁶ es -H, -halo, -CN, -C₁₋₆ alquilo, -O-C₁₋₆ alquilo o -OH; R⁷ es -H, -halo, -CN, -C₁₋₆ alquilo, -O-C₁₋₆ alquilo o -OH; R⁸ es -H, -F o -C₁₋₆ alquilo; R⁹ es -H o -C₁₋₆ alquilo; y R¹⁰ es -H, y R¹¹ es un heterociclo saturado monocíclico de 5 - 7 miembros (que contiene un átomo de nitrógeno y, opcionalmente, un átomo de oxígeno) o un heterociclo bicíclico de 7 miembros (que contiene un átomo de nitrógeno) o -CH₂CH₂NH₂; o NR¹⁰R¹¹ en conjunto forma un heterociclo saturado o insaturado monocíclico o bicíclico de 5 - 7 miembros que contiene un átomo de nitrógeno, en donde el heterociclo se sustituye con 1, 2 ó 3 sustituyentes seleccionados independientemente de la lista que consiste en -NH₂, -C₁₋₆ alquil-NH₂, -NH-C₁₋₆ alquilo, -NHC(=NH)CH₂Cl, -C₁₋₆ alquilo, -halo, -O-C₁₋₆ alquilo, -OH y -C(O)NH₂.
ARP160101486A 2015-05-21 2016-05-20 Compuestos de bencimidazol inhibidores de pad4 AR106863A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562164906P 2015-05-21 2015-05-21

Publications (1)

Publication Number Publication Date
AR106863A1 true AR106863A1 (es) 2018-02-28

Family

ID=56235853

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101486A AR106863A1 (es) 2015-05-21 2016-05-20 Compuestos de bencimidazol inhibidores de pad4

Country Status (15)

Country Link
US (2) US10407407B2 (es)
EP (1) EP3298003B1 (es)
JP (1) JP6703553B2 (es)
KR (1) KR20180005250A (es)
CN (1) CN107849015B (es)
AR (1) AR106863A1 (es)
AU (1) AU2016264958B2 (es)
BR (1) BR112017024678A2 (es)
CA (2) CA2986199C (es)
EA (1) EA033680B1 (es)
ES (1) ES2945314T3 (es)
IL (2) IL255666A (es)
MX (1) MX2017014714A (es)
TW (1) TW201706263A (es)
WO (1) WO2016185279A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
MX2018009773A (es) * 2016-02-23 2018-11-29 Padlock Therapeutics Inc Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
CN109790162B (zh) * 2016-07-27 2022-06-28 帕德罗科治疗公司 Pad4的共价抑制剂
ES2924522T3 (es) 2016-09-12 2022-10-07 Padlock Therapeutics Inc Inhibidores heteroarilo de PAD4
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
WO2019077631A1 (en) * 2017-10-18 2019-04-25 Jubilant Biosys Limited IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
TW201938164A (zh) 2018-01-08 2019-10-01 瑞士商赫孚孟拉羅股份公司 新穎雜環化合物
WO2019152883A1 (en) * 2018-02-02 2019-08-08 Padforward Llc Inhibitors of protein arginine deiminases
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2019180185A1 (en) 2018-03-22 2019-09-26 F. Hoffmann-La Roche Ag Oxazine monoacylglycerol lipase (magl) inhibitors
WO2020033490A1 (en) 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Substituted thienopyrroles as pad4 inhibitors
CN112805066A (zh) * 2018-08-08 2021-05-14 百时美施贵宝公司 作为pad4抑制剂的经取代的苯并咪唑
AU2019319835A1 (en) 2018-08-08 2021-03-25 Bristol-Myers Squibb Company Indole and azaindole inhibitors of PAD enzymes
KR20210042933A (ko) * 2018-08-08 2021-04-20 브리스톨-마이어스 스큅 컴퍼니 Pad 효소의 벤즈이미다졸 억제제
JP2021533093A (ja) 2018-08-13 2021-12-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
CR20210077A (es) 2018-08-13 2021-03-11 Hoffmann La Roche Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
CR20210247A (es) 2018-11-22 2021-06-08 Hoffmann La Roche Nuevos compuestos heterocíclicos
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
KR20220062515A (ko) 2019-09-12 2022-05-17 에프. 호프만-라 로슈 아게 Magl 억제제로서 4,4a,5,7,8,8a-헥사피리도[4,3-b][1,4]옥사진-3-온 화합물
JP2022549304A (ja) 2019-09-24 2022-11-24 エフ．ホフマン－ラ ロシュ アーゲー 複素環化合物
JP2022549306A (ja) 2019-09-24 2022-11-24 エフ．ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ（ｍａｇｌ）の蛍光プローブ
BR112022005472A2 (pt) 2019-09-24 2022-06-14 Hoffmann La Roche Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica
WO2021057910A1 (zh) * 2019-09-27 2021-04-01 南京药捷安康生物科技有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
CN115298175B (zh) * 2020-02-06 2024-05-07 百时美施贵宝公司 可用作免疫抑制剂的大环pad4抑制剂
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環ｐａｄ４抑制劑
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN115551862B (zh) 2020-04-30 2024-04-12 吉利德科学公司 肽基精氨酸脱亚胺酶的大环抑制剂
JP2023538018A (ja) * 2020-08-12 2023-09-06 ジュビラント・エピパッド・エルエルシー ネトーシスの処置及び／又は予防における使用のための方法及び化合物
CN115989228A (zh) 2020-09-03 2023-04-18 豪夫迈·罗氏有限公司 杂环化合物
EP4267562A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
AU2022387714A1 (en) * 2021-11-15 2024-05-30 Regor Pharmaceuticals, Inc. Pad4 inhibitors and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
ATE219934T1 (de) 1995-04-14 2002-07-15 Smithkline Beecham Corp Dosierinhalator für albuterol
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
CN102028994B (zh) 2003-11-03 2013-04-24 葛兰素集团有限公司 流体分配装置
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
SG10201401169QA (en) * 2009-04-02 2014-05-29 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
NO3001903T3 (es) * 2009-12-21 2018-03-24
DK2877467T3 (en) * 2012-07-26 2017-02-13 Glaxo Group Ltd 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4

Also Published As

Publication number Publication date
ES2945314T3 (es) 2023-06-30
CN107849015A (zh) 2018-03-27
CN107849015B (zh) 2021-03-19
WO2016185279A1 (en) 2016-11-24
EA033680B1 (ru) 2019-11-15
US20200095227A1 (en) 2020-03-26
JP2018520105A (ja) 2018-07-26
IL255666A (en) 2018-01-31
EA201792517A1 (ru) 2018-04-30
JP6703553B2 (ja) 2020-06-03
US20180297983A1 (en) 2018-10-18
IL278916A (en) 2021-01-31
BR112017024678A2 (pt) 2018-07-31
CA3199601A1 (en) 2016-11-24
CA2986199C (en) 2023-07-18
AU2016264958B2 (en) 2020-10-29
US10815218B2 (en) 2020-10-27
US10407407B2 (en) 2019-09-10
AU2016264958A1 (en) 2017-12-07
MX2017014714A (es) 2018-01-25
EP3298003B1 (en) 2023-04-19
TW201706263A (zh) 2017-02-16
EP3298003A1 (en) 2018-03-28
CA2986199A1 (en) 2016-11-24
KR20180005250A (ko) 2018-01-15

Similar Documents

Publication Publication Date Title
AR106863A1 (es) Compuestos de bencimidazol inhibidores de pad4
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR106806A1 (es) Inhibidores triazol de acc y usos de los mismos
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR103561A1 (es) Fenilpiridinas herbicidas
CL2020001546A1 (es) Compuestos de 4-azaindol.
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR106798A1 (es) Inhibidores pirazol de acc y usos de los mismos
AR107694A1 (es) Heteroarilos inhibidores de pad4
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR099995A1 (es) Piridilamidinas fungicidas
CU20180144A7 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
AR091022A1 (es) Inhibidores del nampt
AR107032A1 (es) Inhibidores bicíclicos de pad4
CL2015000706A1 (es) Compuestos derivados biciclicos conteniendo nitrogeno y sus sales; su proceso de obtencion; composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de estados patologicos renales, hepaticos, inflamatorios, del sistema nervioso, enfermedades fibroticas y rechazo agudo y cronico del trasplante de organos.
AR088449A1 (es) Benzilindazoles sustituidos
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
EA201891222A1 (ru) Производные иминотетрагидропиримидинона в качестве ингибиторов плазмепсина v
HRP20192279T1 (hr) Novi spojevi imidazopiridazina i njihova uporaba
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
AR094565A1 (es) Compuestos y métodos para tratar infecciones bacterianas
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров

Legal Events

Date Code Title Description
FB Suspension of granting procedure